Mammographic Density and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Gillian Mitchell(Peter MacCallum Cancer Centre), Douglas F. Easton(University of Cambridge), Antonis C. Antoniou(Weatherford College), Lucy Burgess(Birmingham Women's Hospital), Ruth Warren(University of Cambridge), D. Gareth Evans(Manchester Academic Health Science Centre), Louise Izatt(Guy's Hospital), Judith Brown(Cancer Research UK), Trevor Cole(Birmingham Women's Hospital), Margaret Cook(Cancer Research UK), Fiona Douglas(Centre for Life), Joan Paterson, Jenny Mattison(Cancer Research UK), R.S.M. Davies(Royal Devon and Exeter Hospital), Susan Peock(Cancer Research UK), Shirley Hodgson(St Thomas' Hospital), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Diana Eccles(Princess Anne Hospital), Iqbal Warsi(University of Cambridge)
Cited by 132
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k